• LTR Pharma increases its shareholding in LevOmega to ~43% through a A$1m investment
• Strengthens LevOmega's development pathway for pharmaceutical-grade, nature-identical omega-3 ingredients
• Reinforces LTR Pharma's strategy of building a portfolio of first-in-class solutions addressing large, global unmet needs

LTR Pharma Limited (ASX:LTP) has announced that it has increased its ownership in LevOmega Pty Ltd from 33% to approximately 43%. This follows LevOmega's successful completion of a capital raising, which will be used to progress its research and development programs. LTR Pharma's wholly owned subsidiary, LTR Spectrum Pty Ltd, invested A$1.0 million as part of this raise, resulting in its increased ownership position. LevOmega was co-founded by LTR Pharma, Levur Pty Ltd and Green Blue Health Pty Ltd, and is focused on the development of sustainable, pharmaceutical-grade omega-3 products. This strategic investment further strengthens LevOmega's capacity to advance technical validation, pilot production, and commercialisation of its proprietary omega-3 platform. Global demand for omega-3 oils continues to rise, yet marine sources such as fish oil are increasingly constrained by overfishing, pollution, and declining ocean yields. These pressures are creating quality and sustainability challenges for traditional supply chains. LevOmega's focus on developing sustainable, pharmaceutical-grade omega-3 products directly addresses these constraints, offering a scalable and reliable alternative. Omega-3 oil is widely recognised for its cardiovascular and anti-inflammatory health benefits. However, the current reliance on marine harvesting to meet demand is under increasing strain due to overfishing, pollution, and declining yields. Studies note that global nutritional requirements for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) already exceed sustainable marine supply, and environmental changes continue to affect quality and consistency. As a result, demand for nature-identical omega-3 products is expected to rise sharply. Traditional fish oil sources are becoming less reliable and consistent due to worsening global ocean conditions, underscoring the need for scalable, sustainable alternatives.

This strategic investment further strengthens LevOmega's capacity to advance technical validation, pilot production, and commercialisation of its proprietary omega-3 platform.